Julia H. Hayes

TL;DR: In this paper, the authors reviewed evidence from randomized trials and related modeling studies examining the effect of PSA screening vs no screening on prostate cancer-specific mortality and to suggest an approach balancing potential benefits and harms.

TL;DR: Under a wide range of assumptions, for a 65-year-old man, active surveillance is a reasonable approach to low-risk prostate cancer based on QALE compared with initial treatment, however, the QALE gains and the optimal strategy were highly dependent on individual preferences for living under active surveillance and for having been treated.

TL;DR: In this paper, a cost-effectiveness analysis of active surveillance and watchful waiting compared with initial treatment of low-risk, clinically localized prostate cancer in men aged 65 and 75 years was performed.

TL;DR: Among men with newly diagnosed low-risk prostate cancer, observation is more effective and costs less than initial treatment, and WW is most effective and least expensive under a wide range of clinical scenarios.

TL;DR: In this article, a phase II trial was conducted to explore the efficacy and tolerability of RAD001 (10mg daily) in combination with bicalutamide (50mg daily), in men with progressive prostate cancer (CRPC).